B.C. Appeal Court upholds US$30M fraud judgment against West Vancouver man
VANCOUVER – The B.C. Court of Appeal has upheld a US$30 million court judgment against a West Vancouver man alleged by the U.S. government to be the 'mastermind' of a years-long securities fraud.
The ruling says the U.S. Securities and Exchange Commission originally sued Frederick Sharp and others in a Massachusetts court in 2021, and won a default judgment that was recognized by the B.C. Supreme Court last year.
The Appeal Court ruling says Sharp contested the judgment, claiming he had no 'real and substantial connection' to Massachusetts and also arguing he hadn't been properly served with documents related to the case.
The lower court had rejected Sharp's arguments, finding they would 'possibly allow complex international fraud schemes to avoid accountability' if cases were spread across different jurisdictions.
The Appeal Court ruling says the commission provided evidence that Sharp was 'evading' service of the case documents, and the lower court correctly found 'ample evidence' that documents were delivered to Sharp's West Vancouver address.
The appeal ruling released Wednesday says Sharp tried to use expert evidence to show he wasn't 'validly' notified of the U.S. judgment, evidence the commission called an 'irrelevant sideshow.'
This report by The Canadian Press was first published June 25, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
an hour ago
- Winnipeg Free Press
Couche-Tard CEO sees speedier timeline in potential deal for 7-Eleven owner
Alimentation Couche-Tard Inc. executives say the recent process they've adopted to try to buy the owner of 7-Eleven has helped negotiations and perhaps even sped things up. The Laval, Que.-based convenience store operator, which owns Circle K, signed a non-disclosure agreement with Seven & i Holdings Co. Ltd. in May. It also put together a portfolio of U.S. stores it would consider selling in hopes of appeasing regulators and advancing its goal of acquiring 7-Eleven's Japanese parent company. 'I think the benefit of that is it's setting a timeline to bring clarity to both us … and their special committee, if a transaction is going to be reached,' said CEO Alex Miller. 'I believe that timeline will be shorter rather than longer.' The comments offer a window into the talks between the two convenience store giants, whose relations have swung from acrimonious to more tempered since Couche-Tard made a bid for Seven & i last August. Seven & i's board initially rebuffed Couche-Tard's offer, causing it to sweeten its bid by 22 per cent to a reported US$47 billion. Still, Seven & i fought the attempt and eventually garnered a buyout proposal from the family that helped found the Japanese firm. When that fell through, Couche-Tard and Seven & i started mapping out potential buyers for convenience stores that could be sold to satisfy U.S. antitrust regulators. They've said little about how things have progressed since, but Miller mentioned Thursday that only a small group at Couche-Tard is involved with the potential acquisition and engaged with management discussions and due diligence. 'Our focus on mergers and acquisitions, it hasn't changed,' he said. 'I would say activity has not been as pronounced in the recent weeks as it had been over the previous months, but we remain active on some things and we will continue to look at those things as we have always done.' His comments came a day after Couche-Tard revealed it earned US$442.3 million during the fourth quarter, down from US$454.5 million during the same quarter last year. The company, which keeps its books in U.S. dollars, reported net earnings attributable to shareholders came in at US$439.4 million during the quarter, compared to US$453 million during the same period last year. Earnings per diluted share for the period ended April 27 reached 46 cents US during the fourth quarter, compared with 47 cents US during the same period last year. Revenue came in at US$16.3 billion during the fourth quarter, down 7.5 per cent on an annual basis. The quarter encompassed a period of time that was 'not overly rosy' but 'fairly stable.' 'This year has been among the more challenging in retail as our consumers are hurting and carefully watching their spending,' Miller said, in what was likely a reference to the tariff dispute and high cost of living. Yet Canada saw strong demand for fuel and Couche-Tard feels there are more opportunities to expand its market share. Plus, it has also seen 'significant tailwinds' from legislation that allows it to sell alcohol at its Ontario convenience stores. Monday Mornings The latest local business news and a lookahead to the coming week. Miller has seen the addition of booze at locations in the province prove popular and offset losses from nicotine-based products. Moving forward, it will continue its emphasis on expanding food sales. The number of food products the company has sold in the U.S. alone has risen for 14 weeks straight, Miller said, adding that part of the business is in its 'early innings.' It will also focus on personalizing its customer experience. Efforts in that area so far have boosted the number of trips people make to Couche-Tard's stores and how much they spend. This report by The Canadian Press was first published June 25, 2025. Companies in this story: (TSX:ATD)
Cision Canada
2 hours ago
- Cision Canada
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
VANCOUVER, BC, June 26, 2025 /CNW/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns around drug affordability and access. These headwinds are forcing a shift in expectations — placing the burden of innovation on the private sector, where companies like Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Citius Oncology, Inc. (NASDAQ: CTOR), ADC Therapeutics SA (NYSE: ADCT), and OS Therapies Incorporated (NYSE-American: OSTX). The shift reflects more than a funding gap — it signals a structural realignment in how cancer breakthroughs may be brought to market. As public systems face pressure and timelines extend, nimble biotech firms are advancing targeted treatments, combination trials, and regulatory conversations once dominated by legacy institutions. Against this backdrop, market watchers see a pivotal window opening for investors willing to back the next wave of oncology innovation. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new chapter with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. With a background in high-value biotech transactions and late-stage development strategy, Kelly brings experience that may help position the company for its next phase of clinical and corporate progress. Prior to joining Oncolytics, Kelly was General Counsel at Ambrx Biopharma, where he played a key role in the company's $2 billion acquisition by Johnson & Johnson. He also advised a range of life sciences firms on partnerships, licensing, and M&A during his tenure at Kirkland & Ellis LLP and Lowenstein Sandler LLP. His arrival comes as Oncolytics continues advancing pelareorep, a viral-based immunotherapy being evaluated in combination with checkpoint inhibitors and other agents across multiple cancer indications. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment appears aligned with a focused strategy: advancing pelareorep through late-stage development while maintaining capital efficiency and openness to potential partnerships. The company's lead program continues to generate data that support further investigation across several difficult-to-treat cancers. Pelareorep already holds FDA Fast Track designation in two separate indications — metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) — a distinction that highlights regulatory interest in its potential. Across clinical studies, the viral-based immunotherapy has consistently shown signs of immune activation, combinability with checkpoint inhibitors and chemotherapy, and efficacy in heavily pretreated populations. In mPDAC, a Phase 2 cohort from the trial has reported objective response rates (ORR) above 60% in tumor-evaluable patients, exceeding historical benchmarks for this indication. Additional analyses have noted extended two-year survival rates compared to previous benchmarks. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) observed overall survival trends that support continued clinical evaluation. Elsewhere, a Phase 2 anal cancer cohort combining pelareorep with a checkpoint inhibitor demonstrated partial or complete response rates that exceeded historical control trials for checkpoint inhibitor monotherapy, suggesting potential utility beyond the company's lead programs. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." Kelly's compensation framework includes equity-based awards and performance-linked incentives tied to future financings and strategic outcomes. The structure is designed to align leadership priorities with long-term shareholder value while reinforcing a disciplined approach to capital and partnership development. As multiple cohorts advance within the GOBLET study — including those in pancreatic and anal cancers backed by external funding and regulatory support — Oncolytics appears positioned to continue its progress with a blend of clinical momentum, financial flexibility, and sharpened strategic direction. Prior to Kelly's appointment, Oncolytics presented new data from its GOBLET trial at the 2025 ASCO Annual Meeting, highlighting pelareorep's ability to stimulate both innate and adaptive immune responses in metastatic pancreatic cancer. With fresh clinical insights and new leadership in place, the company appears positioned to advance both its scientific and strategic priorities in tandem. In other recent industry developments and happenings in the market include: Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has entered into a strategic partnership with Fosun Pharma to accelerate development of TEV-56278, a novel anti-PD1-IL2 immunotherapy designed using its proprietary ATTENUKINE™ technology. "This partnership with Fosun Pharma in the development of our internally developed TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy with the potential to treat devastating cancers, is the latest advance to ensuring acceleration of our pipeline," said Eric Hughes, MD, PhD, Executive Vice President, Teva Global R&D and Chief Medical Officer. "TEV-56278 demonstrates the strength of Teva's innovative drug development capabilities and how strategic partnerships with companies such as Fosun Pharma play a pivotal role in advancing therapies on behalf of patients." This investigational fusion protein is aimed at selectively delivering IL-2 to PD-1+ T cells, potentially enhancing anti-tumor response while limiting toxic side effects. Under the agreement, Fosun will lead clinical, manufacturing, and commercial activity in China and parts of Southeast Asia, while Teva retains global rights elsewhere. Citius Oncology, Inc. (NASDAQ: CTOR) recently announced that it expects to commercially launch LYMPHIR™ in 2025 for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), pending FDA approval. "We've made steady and meaningful progress toward commercialization over the past several months," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma. "With our supply chain secured, market access supported, and no anticipated impediments to reimbursement, we are encouraged by the momentum we've built. These efforts are pivotal as we transition into a commercial-stage company and believe the planned 2025 launch of LYMPHIR has the potential to be an important inflection point for both the company and the CTCL community." ADC Therapeutics SA (NYSE: ADCT) recently reported updated Phase 2 data from an investigator-initiated trial of ZYNLONTA® in relapsed/refractory marginal zone lymphoma (r/r MZL), showing an 84.6% overall response rate and a 69.2% complete response rate. "Based on the updated Phase 2 IIT data to be shared at ICML, we are encouraged by the potential opportunity in r/r MZL and look forward to seeing additional data, as the trial expands to other sites." said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. "As this trial progresses, assuming the results continue to be positive, we plan to potentially pursue a regulatory pathway and compendia in parallel as soon as sufficient data are available." The trial also showed encouraging durability, with complete responses maintained in 17 of the 18 patients who achieved a complete response and progression-free survival of 92.9% at 12 months. ZYNLONTA was generally well tolerated, with safety findings consistent with its existing clinical profile. OS Therapies Incorporated (NYSE-American: OSTX) received positive written feedback from the FDA following a Type D meeting regarding its lead candidate, OST-HER2, for pediatric lung metastatic osteosarcoma. "We are pleased with the feedback we received from the FDA regarding the use of external control comparators in settings where placebo-controlled randomization trials are not feasible – particularly in rare pediatric diseases such as the indication treated by OST-HER2 ," said Dr. Robert Petit, Chief Medical & Scientific Officer of OS Therapies. "Moreover, we received additional collaborative input regarding suggested statistical methods as we seek to compare OST-HER2 active treatment with external control arm(s) to support a Biologics Licensing Application (BLA) via the Accelerated Approval Program. Taken together, the feedback gives us insight on the FDA's current position and allows us to be fully prepared for the End of Phase 2 Meeting." The agency supported the company's proposed use of external comparators in its Phase 2b trial, potentially laying groundwork for accelerated approval. OS Therapies has submitted requests for an End of Phase 2 Meeting and Breakthrough Therapy Designation, with regulatory filings expected to advance in late 2025. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
The Market Online
2 hours ago
- The Market Online
Freeport-McMoRan funds B.C. gold miner's new drilling program
Junior miner ArcWest Exploration (TSXV:AWX), market capitalization C$10.38 million, will break ground on a drill program at its Todd Creek copper-gold project in B.C. by the end of June The program is fully funded with at least C$4 million from Freeport-McMoRan Mineral Properties Canada ArcWest is a mining project generator creating value through porphyry copper-gold exploration in western North America ArcWest Exploration stock has given back 3.85 per cent year-over-year but remains up by 78.57 per cent since 2020 Junior miner ArcWest Exploration (TSXV:AWX), market capitalization C$10.38 million, will break ground on a drill program at its Todd Creek copper-gold project in B.C.'s Golden Triangle by the end of June. The program is fully funded with at least C$4 million from Freeport-McMoRan Mineral Properties Canada – a subsidiary of Freeport-McMoran (NYSE:FCX), market capitalization US$63.34 billion – under the companies' 2023 earn-in agreement, which grants the global metals player the right to earn a 51 per cent interest in Todd Creek by spending C$20 million over five years and making staged cash payments to ArcWest. Drilling will test four porphyry copper-gold targets defined through robust geophysical, geochemical and geological mapping during the 2023-2024 field seasons, also part of Freeport's earn-in. Work will be overseen by the same Freeport technical team behind the recent high-grade Aurora porphyry copper-gold discovery in northern B.C. in partnership with Amarc Resources. The 21,700-hectare Todd Creek project hosts a 13-kilometre-long zone of contained copper-gold mineral occurrences, many of which, according to Thursday's news release, went underexplored in historical drilling. The project adjoins Newmont's Brucejack gold mine, one of the world's highest-grade producers, and is located about 40 kilometres southeast of Seabridge Gold's KSM-Iron Cap deposits, one of the largest copper-gold concentrations in North America. Leadership insights 'Our work with Freeport to date at Todd Creek demonstrates that the property is host to one of the largest underexplored copper-gold systems in B.C.,' Tyler Ruks, ArcWest Exploration's president and chief executive officer, said in a statement. 'The 2025 Todd Creek drill program represents the culmination of two years of extensive field work, which has outlined multiple drill targets on the property. ArcWest is excited to begin testing if the gold-copper mineralization, which occurs near surface along a 13-kilometre-long trend, is related to one or more underlying porphyry copper-gold systems.' 'ArcWest remains in a strong financial position with C$2.65 million hard dollars in the treasury as of May 30th, 2025, in addition to marketable securities worth C$391,489,' 'no warrants, significant insider ownership and a low burn rate,' Ruks added. 'Anticipated income for ArcWest between now and the end of the year totals approximately C$375,000, including option and share payments from earn-in partners, in addition to operatorship fees for ArcWest managed exploration programs.' About ArcWest Exploration ArcWest is a mining project generator creating value through porphyry copper-gold exploration in western North America. The company's portfolio includes seven projects throughout B.C. ArcWest Exploration stock (TSXV:AWX) is up by 38.89 per cent on the news trading at C$0.12 as of 9:55 am ET. The stock has given back 3.85 per cent year-over-year but remains up by 78.57 per cent since 2020. Join the discussion: Find out what everybody's saying about this Canadian copper-gold stock on the ArcWest Exploration Inc. Bullboard and check out the rest of Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
